Zanos et al. reply
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In the accompanying Comment1, Suzuki et al. confirmed our previous findings2 that the ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) does not functionally inhibit the NMDAR at concentrations relevant to its antidepressant actions recently reported in mice (that is, approximately 10 μM). We reported that 10 μM (2R,6R)-HNK, which equates to the maximum concentration of brain exposure (10.69 μM (ref. 2)) after intraperitoneal administration of a 10 mg kg−1 anti depressant dose of (2R,6R)-HNK in mice, robustly potentiated excitatory postsynaptic potentials in hippocampal slices without functionally inhibiting the NMDAR2, as Suzuki et al. now confirm. Unless NMDAR inhibition is observed at 10 μM (2R,6R)-HNK, it is probably not of major relevance to the antidepressant actions of (2R,6R)-HNK. Notably, (2R,6R)-HNK administration also resulted in significant antidepressant actions at the dose of 5 mg kg−1 in mice, which would produce even lower concentrations of the metabolite in the brain than 10 μM (ref. 2). Furthermore, our field-potential electrophysiology experiments were conducted in the presence of the NMDAR antagonist AP5 (80 μM), demonstrating that the AMPAR-mediated synaptic potentiation we observed is indepen dent of any capacity of (2R,6R)-HNK to inhibit the NMDAR. We agree with Suzuki et al. that assessing higher concentrations of (2R,6R)-HNK on NMDAR-mediated miniature excitatory postsynaptic currents (NMDAR-mEPSCs) responses might be important in providing information for off-target effects of this metabolite, and their study indeed provides evidence for a modest inhibition (~ 37%) at the concentration of 50 μ M. The absence of Mg2+ in the testing conditions may influence the apparent discrepancy between 37% inhibition of NMDAR-mEPSCs at the 50 μ M concentration (for example, as is the case with memantine, which only inhibits NMDAR-mEPSCs in the absence of Mg2+, and does not have antidepressant properties in humans3), and the previously reported lack of displacement of [3H] MK-801 binding at less than 100 μ M (ref. 4). It will be important to follow up on this finding with a full concentration response curve in order to determine the half maximal inhibi tory concentration (IC50) of (2R,6R)-HNK on NMDAR-mEPSC responses, and to compare to the IC50 of (R,S)-ketamine, under the same conditions using physiological levels of Mg2+. Notably, we did not observe NMDAR-inhibitionassociated psychostimulant, self-administration, drug discrimination and pre-pulse inhibition side effects of (2R,6R)-HNK at any dose, including up to 375 mg kg−1 (ref. 2). The authors also observed decreased phosphorylation of the eukaryotic elongation factor 2 (eEF2) only at the concentration of 50 μ M. Although this is the same high concentration at which (2R,6R)-HNK induced an inhibition of the NMDAR responses, these data do not provide direct evidence of a functional link between the moderate inhibition of NMDARs and the decrease in eEF2 phosphorylation. Indeed there are multiple mechanisms other than NMDAR inhibition that could be responsible for the observed eEF2 dephosphorylation5–8. It is also important to note that although direct application of ketamine9 or the alternative NMDAR blocker MK-801 (ref. 10) to cultured neurons or hippocampal slices was previously reported to induce NMDAR-inhibition-dependent synaptic potentiation, MK-801 has repeatedly failed to induce ketamine-like sustained antidepressant effects in several animal tests2,9,11,12. It is therefore probable that synaptic strengthening as a consequence of NMDAR inhibition (proposed by Suzuki et al.) is not solely responsible for the antidepressant actions of ketamine. Indeed, the results of clinical trials indicate that several other NMDAR antagonists lack the full antidepressant actions of ketamine in humans13. Suzuki et al. also propose that NMDAR inhibition by (R,S)ketamine is responsible for the initiation of antidepressant responses (that is, the acute actions), and HNK metabolites mediate the longterm antidepressant effects of ketamine through continued NMDAR inhibition. This hypothesis is not supported by our pharmacokinetic measurements of ketamine and its metabolites in the brain of mice following intraperitoneal administration of (R,S)-ketamine, which show that both ketamine and its metabolites peak at similar early time points, have a similar short half-life, and are below detectable levels by four hours after treatment2. In conclusion, the data presented by Suzuki et al. further support an NMDAR-inhibition-independent mechanism of antidepressant action of the ketamine metabolite (2R,6R)-HNK at physiologically relevant concentrations. Although development of (2R,6R)-HNK as an anti depressant drug, which does not induce NMDAR-mediated side effects, can proceed independently of target identification, it remains important to identify its primary pharmacological target at anti depressant-relevant concentrations (~ 10 μ M). Author Irving W. Wainer has chosen not to be listed on this Reply.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
Effects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180
Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Self-citation
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Self-citationDe Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Self-citationLumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Self-citation
Metadata
- Authors
- Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., Dossou, K. S. S., Fang, Y., Huang, X.-P., Mayo, C. L., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., & Gould, T. D.
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7659
- Pages
- E4-E5
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2664605305
- Cited by
- 34
- References
- 8
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zanos et al. reply. https://app.cochat.ai/papers/10.1038/nature22085
- The paper
- Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., Dossou, K. S. S., Fang, Y., Huang, X.-P., Mayo, C. L., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., & Gould, T. D. (2017). Zanos et al. reply. Nature. https://doi.org/10.1038/nature22085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.